GeneQuantum and AIMEDBIO Collaborate on First-in-Class Antibody-Drug Conjugate


SUZHOU, China, April 18, 2022 /PRNewswire/ — GeneQuantum Healthcare (Suzhou) Co., Ltd., a company specializing in site-specific bioconjugation for next-generation biotherapeutics, has signed an agreement with a Korean biotechnology company, Aimed Bio Inc., to to co-develop a first-in-class therapeutic antibody-drug conjugate (ADC). Aimed Bio, a spin-off company from Samsung Medical Center, is focused on developing innovative antibody-focused drugs for brain diseases with few treatment options. Additional details were not disclosed.

GeneQuantum is focused on the development of next-generation antibody-drug conjugates (ADCs). Leveraging the proprietary “Ligase Dependent Conjugation” (LDC) technology platform, which enables site-specific conjugation of cytotoxins or other types of payloads to antibodies, the company has successfully developed a robust pipeline with more of 10 assets, several of which are at or approaching clinical stage. In addition to expanding the unique technology platform, the company has entered into a number of partnerships with domestic biotech/pharmaceutical companies and international partners. The growing number of partnerships demonstrates the power of the GeneQuantum platform technology to not only improve key therapeutic characteristics of existing molecules, but also to create new classes of molecules, thereby increasing the number of treatment options available to patients. patients from all over the world. GeneQuantum is excited about the significant potential of partnerships with commercial partners and will continue to expand its transaction portfolio in the antibody-drug conjugate (ADC) and protein therapeutics market.

Collaborator ADC is a first class asset with highly differentiated antibody against single target, stable linker design and novel payload with strong bystander killing effect. The resulting ADC should treat brain and other cancers with huge unmet needs.

Dr. Gang Qin, Founder and Chairman, CEO of GeneQuantum, said, “As an innovative antibody+ company, we are looking for complementary partners to maximize the value of our platform technology. Aimed Bio not only has differentiated antibodies acting on a single target, but also has in-depth knowledge and expertise in the field of brain tumors and CNS diseases This collaboration is based on an excellent match between the two companies to generate a CAN-FIC. Through a close partnership, we are excited to bring breakthrough therapy to patients without effective treatment at this time..”

dr. Dohyunnamthe Founder and Chairman, CTO of Aimed Bio and an internationally renowned neurosurgeon with 32 years of experience in brain tumors and CNS diseases, said: “Aimed Bio has successfully expanded its R&D pipeline over the past 2 years, and I am delighted to begin this collaboration with GeneQuantum. After evaluating the data, the binding and conjugation payload technology provided by GeneQuantum has been found to be very safe and effective. With the best expertise of Aimed Bio When it comes to antibodies and brain tumors, I think the ADC collaborating will have a huge impact on the We look forward to getting the clinical trial started as soon as possible.”

The new drug is expected to enter the IND in 2023.

About GeneQuantum Healthcare (Suzhou) Co., Ltd.

GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech biopharmaceutical company dedicated to the development of innovative biotherapeutic products. The Company is focused on developing a new generation of therapeutic bioconjugates to address the unmet medical needs of cancer patients worldwide. For more information, visit


AIMEDBIO is a spin-off company from Samsung Medical Center (SMC) based in August 2018. AIMEDBIO aims to bring therapeutic solutions to patients with serious brain diseases, including neuro-oncological and degenerative diseases, to save patients’ lives and improve patients’ quality of life. Leveraging strong global networks with key opinion leaders in the field, an excellent research team with deep accomplishments, and R&D pipelines with an exceptional drug development platform, AIMEDBIO is an emerging leader for the development of innovative therapies against various brain diseases.

SOURCE GeneQuantum Healthcare


Comments are closed.